Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi Dose, Open-Label, Parallel-Group Study to Evaluate the PK and Safety/Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder

Next Previous
X
Search
Trial Profile

A Multi Dose, Open-Label, Parallel-Group Study to Evaluate the PK and Safety/Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizophrenia
  • Focus Pharmacokinetics; Registrational
  • Acronyms STARLYNG-1
  • Sponsors Lyndra

    • Most Recent Events

    • 04 Jan 2024 According to a Lyndra Therapeutics media release, Status changed from recruiting to discontinued.
    • 04 Jan 2024 According to a Lyndra Therapeutics media release, Primary endpoint (Average Concentration Over the Dosing Interval (Cavg) at Week 5) has been met.
    • 04 Jan 2024 According to a Lyndra Therapeutics media release, Primary endpoint (Maximal Observed Concentration (Cmax) at Week 5) has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top